Format

Send to

Choose Destination
Infect Drug Resist. 2008;1:27-44. Epub 2008 Sep 9.

Current and novel antibiotics against resistant Gram-positive bacteria.

Author information

1
Division of Infectious Diseases and HIV Medicine, University Hospitals Case Medical Center, Cleveland OH, USA;

Abstract

The challenge posed by resistance among Gram-positive bacteria, epitomized by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE) and vancomycin-intermediate and -resistant S. aureus (VISA and VRSA) is being met by a new generation of antimicrobials. This review focuses on the new β-lactams with activity against MRSA (ceftobiprole and ceftaroline) and on the new glycopeptides (oritavancin, dalbavancin, and telavancin). It will also consider the role of vancomycin in an era of existing alternatives such as linezolid, daptomycin and tigecycline. Finally, compounds in early development are described, such as iclaprim, friulimicin, and retapamulin, among others.

KEYWORDS:

Gram-positive bacteria; anti-MRSA cephalosporins; daptomycin; linezolid; lipoglycopeptides; tigecycline; vancomycin

PMID:
21694878
PMCID:
PMC3108725

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center